Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4776)
All Articles published online
|
Publishing Process of This Article
|
Jul 15, 2022 (publication date) through May 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2022; 14(7): 1252-1264 [PMID: 36051096 DOI: 10.4251/wjgo.v14.i7.1252] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v14/i7/1252.htm |
| Number | Citing Articles |
| 1 |
Guocheng Zhong, Xiaomin Zhang, Zheng Guo, Yujie Gao, Bochen Zhao, Xianhao Liu, Lei Chen, Jingqiao Qiao, Chuan Yu, Lixin Wang, Yisheng Li, Li Yu. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case report. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1325860
|
| 2 |
Caroline Hana, Nyein Nyein Thaw Dar, Michael Galo Venegas, Michel Vulfovich. Claudins in Cancer: A Current and Future Therapeutic Target. International Journal of Molecular Sciences 2024; 25(9): 4634 doi: 10.3390/ijms25094634
|
| 3 |
Tongxin Zhang, Zilong He, Yankui Liu, Linfang Jin, Teng Wang. High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric Cancer. International Journal of General Medicine 2024; : 1695 doi: 10.2147/IJGM.S453883
|
| 4 |
Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W.M. De Groof, Nick Devoogdt. Current status and future expectations of nanobodies in oncology trials. Expert Opinion on Investigational Drugs 2023; 32(8): 705 doi: 10.1080/13543784.2023.2249814
|
| 5 |
Yuming Wang, Yike Gao, Zhiwen Zhang, Zixin Zhang, Anqi Wang, Kun Zhao, Miao Zhang, Sumei Zhang, Mei Li, Jian Sun, Dan Guo, Zhiyong Liang. Claudin18.2 expression in pulmonary mucinous adenocarcinoma. Journal of Cancer Research and Clinical Oncology 2023; 149(14): 12923 doi: 10.1007/s00432-023-05150-x
|
| 6 |
Pankti C. Balar, Vasso Apostolopoulos, Vivek P. Chavda. A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way. European Journal of Pharmacology 2024; 969: 176451 doi: 10.1016/j.ejphar.2024.176451
|
| 7 |
Annalisa Schirizzi, Aram Arshadi, Doron Tolomeo, Laura Schirosi, Anna Maria Valentini, Giampiero De Leonardis, Maria Grazia Refolo, Rossella Donghia, Clelia Tiziana Storlazzi, Alfredo Zito, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Maria Bencivenga, Giovanni De Manzoni, Caterina Messa, Raffaele Armentano, Gianluigi Giannelli, Claudio Lotesoriere, Rosalba D’Alessandro. VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment. Biomedicines 2023; 11(10): 2721 doi: 10.3390/biomedicines11102721
|
| 8 |
Chen Wang, Na Wu, Beibei Pei, Xiaoyan Ma, Wenhui Yang. Claudin and pancreatic cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1136227
|
| 9 |
Marta Łukaszewicz-Zając, Barbara Mroczko. Claudins—Promising Biomarkers for Selected Gastrointestinal (GI) Malignancies?. Cancers 2023; 16(1): 152 doi: 10.3390/cancers16010152
|
| 10 |
Jinxia Chen, Zhiyuan Xu, Can Hu, Shengjie Zhang, Mengli Zi, Li Yuan, Xiangdong Cheng. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1132319
|
| 11 |
Izuma Nakayama, Changsong Qi, Yang Chen, Yoshiaki Nakamura, Lin Shen, Kohei Shitara. Claudin 18.2 as a novel therapeutic target. Nature Reviews Clinical Oncology 2024; 21(5): 354 doi: 10.1038/s41571-024-00874-2
|